Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

319
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
319
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

414
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
414
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

581
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
581

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic analysis according to adjuvant chemotherapy and anti-HER2 therapy following surgery in T1a/b HER2-positive breast cancer.

The Korean journal of internal medicine·2026
Same author

Prognostic impact of close margins on Loco-regional recurrence in ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Transforming unstructured breast cancer pathology reports into the Observational Medical Outcomes Partnership Common Data Model.

BMC medical informatics and decision making·2026
Same author

Oncological safety and preventive impact of nipple-sparing mastectomy in patients with BRCA1/2 mutation: multicentre study of the Korea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG).

BJS open·2026
Same author

Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Neutrophil- and Platelet-to-Lymphocyte Ratios as Predictive Markers for Capsular Contracture after Immediate Implant-Based Reconstruction.

Plastic and reconstructive surgery·2026

Related Experiment Video

Updated: Nov 5, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.9K

The Potential Predictors in Chemotherapy Sensitivity.

Eun-Kyu Kim1, Hee-Chul Shin2

  • 1Department of Surgery, Seoul National University Bundang Hospital, Seoul, South Korea. ekkim.md@gmail.com.

Advances in Experimental Medicine and Biology
|May 13, 2021
PubMed
Summary

Genetic variations in patients can predict how well chemotherapy works and if it causes side effects. These germline and somatic variants, impacting drug metabolism and immune response, serve as potential biomarkers for personalized cancer treatment.

Keywords:
BiomarkersBreast oncologyCancer cell sensitivityChemotherapyPharmarcogenetic

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Related Experiment Videos

Last Updated: Nov 5, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.9K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Area of Science:

  • Pharmacogenomics and Cancer Therapeutics
  • Molecular Oncology and Biomarker Discovery

Background:

  • Chemotherapy effectiveness monitoring is crucial for patient outcomes.
  • Somatic mutations are primary indicators of chemotherapy response.
  • Germline variants and immune system genetics also influence drug efficacy and toxicity.

Purpose of the Study:

  • To explore the role of germline and somatic genomic variations in predicting chemotherapy response.
  • To identify genetic variations as potential biomarkers for chemotherapeutic agents like cyclophosphamide and paclitaxel.
  • To understand how genomic variations affect drug pharmacokinetics and patient sensitivity.

Main Methods:

  • Analysis of patient germline and somatic genomic data.
  • Correlation of genetic variants with drug enzyme activities.
  • Assessment of immune system genetic variations in relation to drug response.
  • Evaluation of pharmacokinetic profiles influenced by genomic variations.

Main Results:

  • Germline variants may predict cancer cell sensitivity to chemotherapy.
  • Altered drug enzyme activities due to variants can predict response to agents like cyclophosphamide and paclitaxel.
  • Genomic variations influence chemotherapy pharmacokinetics, acting as potential biomarkers.
  • Patient's genetic makeup, including immune system variations, is linked to drug response and toxicity.

Conclusions:

  • Germline and somatic genomic variations are significant predictors of chemotherapy efficacy and toxicity.
  • Identifying these variations can lead to personalized chemotherapy strategies.
  • Genomic biomarkers hold promise for optimizing cancer treatment and improving patient outcomes.